Reported herein is a visible‐light‐mediated radical approach to the α‐alkylation of ketones. This method exploits the ability of a nucleophilic organocatalyst to generate radicals upon SN2‐based activation of alkyl halides and blue light irradiation. The resulting open‐shell intermediates are then intercepted by weakly nucleophilic silyl enol ethers, which would be unable to directly attack the alkyl
Effect of alkyl and aryl substitutions on 1,2,4-triazolium-based ionic liquids for carbon dioxide separation and capture
作者:Patrick C. Hillesheim、Joseph A. Singh、Shannon M. Mahurin、Pasquale F. Fulvio、Yatsandra Oyola、Xiang Zhu、De-en Jiang、Sheng Dai
DOI:10.1039/c2ra22646d
日期:——
significant changes allowing for development of task-specific triazolium-based ionicliquids for separation applications. COSMOtherm studies were also completed to gain a better understanding of the ionicliquids which demonstrated a strong correlation between experimental and computational values for the alkyl bearingionicliquids. Hence, 1,2,4-triazolium-based liquids comprise a class of compounds offering
[EN] BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLYL-MÉTHYLURÉE EN TANT QU'AGONISTES DU RÉCEPTEUR ALX
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2015019325A1
公开(公告)日:2015-02-12
The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula
wherein A
1
, A
2
, R
1
, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.
[EN] GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY<br/>[FR] COMPOSES MODULATEURS DE RECEPTEURS DE GLUCOCORTICOIDE ET PROCEDES
申请人:LIGAND PHARM INC
公开号:WO2005082909A1
公开(公告)日:2005-09-09
Provided herein are compounds of Formula (I) and pharmaceutically acceptable derivatives thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also provided are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.